Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Production of Antibiotics

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...

Scale-Up Processes

Scale-Up Processes

The scale-up of microbial fermentation processes is essential in industrial biotechnology, allowing the transition from laboratory-scale experiments to commercial-scale production while aiming to maintain product yield and quality. This process requires meticulous adjustment of equipment design, process parameters, and contamination control strategies to accommodate increasing culture volumes.At the laboratory scale, cultures are typically maintained in 1 to 10-liter glass or autoclavable...

Bioreactor Controls-III

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recombinant Protein Drugs: A 2025 Update.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same author

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.

ACS materials letters·2026

Same author

A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.

ACS materials letters·2026

Same author

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.

Biomaterials advances·2026

Same author

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026

Same author

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates.

Materials today. Bio·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

Microbial factories for recombinant pharmaceuticals.

Neus Ferrer-Miralles¹, Joan Domingo-Espín, José Luis Corchero

¹Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain. antoni.villaverde@uab.cat.

Microbial Cell Factories

|March 26, 2009

Summary

Microbial systems like bacteria and yeast are robust hosts for producing approved recombinant protein drugs, despite challenges in mammalian protein production. Their continued use highlights their effectiveness in biopharmaceutical manufacturing.

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

Related Experiment Videos

Last Updated: Jun 24, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

Area of Science:

Biotechnology and Biopharmaceutical Manufacturing
Recombinant Protein Production
Microbial Host Systems

Background:

151 recombinant pharmaceuticals approved by FDA/EMEA primarily use microbial hosts (bacteria, yeast).
Microbial systems present challenges: unconventional post-translational modifications, proteolytic instability, poor solubility, and cell stress responses.
Despite challenges, microbial systems remain powerful tools for recombinant protein production.

Purpose of the Study:

To summarize the nature, properties, and applications of approved recombinant pharmaceuticals.
To comparatively analyze features of current and potential microbial host systems for protein drug production.

Main Methods:

Review and comparative analysis of existing literature on recombinant pharmaceuticals.
Evaluation of microbial production systems (Escherichia coli, Saccharomyces cerevisiae) and their performance.
Assessment of challenges and advantages associated with microbial protein production.

Main Results:

Microbial systems, particularly E. coli and S. cerevisiae, are extensively used and proven robust for producing approved recombinant drugs.
The market entry of protein drugs from non-microbial systems has not diminished the development of microbially produced biologics.
Despite inherent production bottlenecks, microbial systems offer a reliable platform for biopharmaceutical development.

Conclusions:

Microbial cellular systems are indispensable and robust platforms for the production of a significant number of biopharmaceuticals.
Continued innovation in microbial strain development and process optimization is crucial for future recombinant protein drug manufacturing.
Comparative analysis of host systems underscores the enduring value and potential of microbial production platforms.